Cryoport Inc (CYRX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Cryoport Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 14 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 15.10 $ — 85% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -7.5% failed
- More than 10% revenue growth is expected for the coming year 9.6% failed
- Share count grows by less than 3% a year 2.9% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -40.4% failed
- Gross margin at 40% or higher and without meaningful erosion 47.1% passed
- Goodwill from acquisitions does not grow faster than revenue 2.9% passed
- Net debt below twice EBITDA 180 m net cash passed
- Operating cash flow covers the profits of the last three years 33 m failed
- Return on capital at 15% or higher, or up versus two years ago -6.7% failed
- Insiders hold at least 10% or are net buyers 3.9% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 13.0% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.73 | -0.78 – -0.68 | 194 | -8.1% | 3 |
| 12/31/2027 | -0.62 | -0.65 – -0.58 | 213 | 15.5% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.20 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.38 | – | 60 | 4.00 | -31.40 | -6 | -11 |
| 2025: Q1 | -0.24 | – | 41 | 10.10 | -29.20 | -4 | -8 |
| 2025: Q2 | 2.09 | – | 46 | 14.50 | 231.40 | -7 | -12 |
| 2025: Q3 | -0.14 | -950.30 | 44 | -21.90 | -15.70 | 2 | -2 |
| 2025: Q4 | -0.23 | – | 46 | -23.70 | -25.60 | 1 | -4 |
| 2026: Q1 | -0.19 | – | 48 | 16.50 | -19.70 | 4 | -7 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 8 | -9 | -13 | -0.92 | -6 | 6 | 8 |
| 2017 | 12 | -8 | -8 | -0.34 | -4 | 18 | 20 |
| 2018 | 20 | -9 | -10 | -0.34 | -3 | 39 | 57 |
| 2019 | 34 | -18 | -18 | -0.55 | -1 | 126 | 136 |
| 2020 | 79 | -30 | -33 | -0.85 | -15 | 383 | 552 |
| 2021 | 223 | -18 | -276 | -6.00 | 8 | 642 | 1,113 |
| 2022 | 223 | -18 | -276 | -6.00 | -2 | 556 | 1,039 |
| 2023 | 237 | -32 | -37 | -0.76 | -1 | 489 | 958 |
| 2024 | 233 | -115 | -100 | -2.04 | -16 | 402 | 703 |
| 2025 | 176 | -37 | 78 | 1.56 | -9 | 503 | 765 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Cryoport, Inc. bietet weltweit temperaturkontrollierte Lieferketten-Lösungen für die Märkte Biopharma/Pharma, Tiergesundheit und Reproduktionsmedizin an.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 684 |
| Headquarters | Brentwood, TN |
| Address | 112 Westwood Place, 37027 Brentwood, United States |
| Phone | 949 470 2300 |
| Website | cryoportinc.com |
| IPO Date | 15. Mar 2005 |
| ISIN | US2290503075 |
| Stock Split | 1:12 on 05/19/2015 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jerrell W. Shelton | Chairman, President & CEO | 1945 |
| Robert S. Stefanovich MS | Senior VP, CFO, Treasurer & Chief Administrative Officer | 1965 |
| Edward J. Zecchini | Senior VP and Chief Digital & Technology Officer | 1962 |
| Mark W. Sawicki Ph.D. | Senior VP & Chief Scientific Officer | – |
| Thomas J. Heinzen | Vice President of Corporate Development & Investor Relations | – |
| Tony Ippolito | VP, General Counsel & Corporate Secretary | – |
| Kylie A. Crowe | Vice President of Global Human Resources & Organizational Development | – |
| Phil Wilson | Chief Operating Officer of Cryoport Systems, LLC | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.